Innovative Biotech OncoLize Secures $1.7 Million in Seed Funding for Groundbreaking Tumor Treatment Technology

OncoLize, the innovative Dutch biotech company dedicated to revolutionizing cancer treatment, has successfully raised €1.7 million in funding to further develop its groundbreaking ChemoGell™ platform. This novel approach allows clinicians to treat tumors from within by injecting drugs directly into the tumor mass, maximizing efficacy while minimizing systemic exposure. The ChemoGell™ technology, protected by a robust suite of patents recently granted in key markets including the US, EU, China, and Japan, is based on advanced hydrogel technology developed at the Royal College of Surgeons in Ireland by esteemed professor Dr. Helena Kelly. OncoLize's collaboration with the Gastro-Oncology team at Leiden University Medical Center has already yielded remarkable results, demonstrating 100% survival rates in pancreatic cancer mice models when treated with their ChemoGell™, compared to a stark 0% survival for those not receiving the treatment. The funding will enable OncoLize to expand its research efforts to include additional cancer types, including gastric and ovarian cancers, bolstered by recent grants from the Dutch Cancer Foundation. Furthermore, the scalable, cost-effective nature of ChemoGell™ means it can be easily produced at scale by contract manufacturing organizations and hospital pharmacies alike, underscoring its potential as a game-changer in oncology therapeutics. With this pivotal funding, OncoLize is poised to drive forward its mission of delivering new, effective treatment modalities to cancer patients globally, truly exemplifying its mantra to "Treat Tumors from the Inside."